【摘要】 目的观察艾曲波帕联合重组人血小板生成素治疗妇科肿瘤放化疗后血小板减少症的疗效。方法回顾性分析在我院住院治疗的67例妇科肿瘤放化疗后血小板减少症患者的资料,分为艾曲波帕联合重组人血小板生成素(rhTPO)治疗的观察组33例和单用重组人血小板生成素治疗的对照组34例,比较两组临床疗效及药物不良反应。结果治疗前两组的血小板计数差异无统计学意义(P>0.05)。治疗后第3、7、14天,两组血小板计数均有上升,且观察组的上升程度大于对照组,差异有统计学意义(P<0.05)。两组均未出现明显药物不良反应。结论艾曲波帕联合重组人血小板生成素治疗妇科肿瘤放化疗后血小板减少症的疗效显著,能更快提升患者血小板计数。更多还原

【Abstract】 Objective To observe the clinical efficacy of eltrombopag combined with recombinant human thrombopoietin(rhTPO)in the treatment of thrombocytopenia after radiotherapy and chemotherapy of gynecological tumor.Methods The data of 67 patients with thrombocytopenia in our hospital was analyzed retrospectively.They were divided into two groups:the observation group(33 cases)treated with eltrombopag combined with rhTPO and the control group(34 cases)treated with rhTPO alone.The clinical efficacy,platelet and adverse drug reactions were compared between the two groups.Results There was no significant difference in platelet count between the two groups before treatment(P>0.05).On the 3 rd,7 th and 14 th day after treatment,the platelet count of the both groups increased,and the increase degree of the observation group was greater than that of the control group(P<0.05).There were no significant adverse drug reactions in both two groups.Conclusion Eltrombopag combined with rhTPO has a significant efficacy in the treatment of thrombocytopenia after radiotherapy and chemotherapy of gynecological tumor,which can increase the platelet count faster.更多还原